Autism Spectrum Disorders and the Gut Microbiota

Antonella Fattorusso, Lorenza Di Genova, Giovanni Battista Dell'Isola, Elisabetta Mencaroni, Susanna Esposito, Antonella Fattorusso, Lorenza Di Genova, Giovanni Battista Dell'Isola, Elisabetta Mencaroni, Susanna Esposito

Abstract

In recent years, there has been an emerging interest in the possible role of the gut microbiota as a co-factor in the development of autism spectrum disorders (ASDs), as many studies have highlighted the bidirectional communication between the gut and brain (the so-called "gut-brain axis"). Accumulating evidence has shown a link between alterations in the composition of the gut microbiota and both gastrointestinal and neurobehavioural symptoms in children with ASD. The aim of this narrative review was to analyse the current knowledge about dysbiosis and gastrointestinal (GI) disorders in ASD and assess the current evidence for the role of probiotics and other non-pharmacological approaches in the treatment of children with ASD. Analysis of the literature showed that gut dysbiosis in ASD has been widely demonstrated; however, there is no single distinctive profile of the composition of the microbiota in people with ASD. Gut dysbiosis could contribute to the low-grade systemic inflammatory state reported in patients with GI comorbidities. The administration of probiotics (mostly a mixture of Bifidobacteria, Streptococci and Lactobacilli) is the most promising treatment for neurobehavioural symptoms and bowel dysfunction, but clinical trials are still limited and heterogeneous. Well-designed, randomized, placebo-controlled clinical trials are required to validate the effectiveness of probiotics in the treatment of ASD and to identify the appropriate strains, dose, and timing of treatment.

Keywords: Autism spectrum disorder; brain; gut microbiota; microbiota transfer therapy; probiotic.

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Ozonoff S., Young G.S., Carter A., Messinger D., Yirmiya N., Zwaigenbaum L., Bryson S., Carver L.J., Constantino J.N., Dobkins K., et al. Recurrence risk for autism spectrum disorders: A Baby Siblings Research Consortium study. Pediatrics. 2011;128:e488–e495. doi: 10.1542/peds.2010-2825.
    1. Doernberg E., Hollander E. Neurodevelopmental disorders (ASD and ADHD): DSM-5, ICD-10, and ICD-11. CNS Spectr. 2016;21:295–299. doi: 10.1017/S1092852916000262.
    1. Risch N., Hoffmann T.J., Anderson M., Croen L.A., Grether J.K., Windham G.C. Familial recurrence of autism spectrum disorder: Evaluating genetic and environmental contributions. Am. J. Psychiatry. 2014;171:1206–1213. doi: 10.1176/appi.ajp.2014.13101359.
    1. Kraneveld A.D., Szklany K., de Theije C.G., Garssen J. Gut-to-brain axis in autism spectrum disorders: Central role for the microbiome. Int. Rev. Neurobiol. 2016;131:263–287.
    1. Li Q., Han Y., Dy A.B.C., Hagerman R. The Gut Microbiota and Autism Spectrum Disorders. Front. Cell. Neurosci. 2017;11:120. doi: 10.3389/fncel.2017.00120.
    1. Estes M.L., McAllister A.K. Immune mediators in the brain and peripheral tissues in autism spectrum disorder. Nat. Rev. Neurosci. 2015;16:469–486. doi: 10.1038/nrn3978.
    1. Doenyas C. Gut Microbiota, Inflammation, and Probiotics on Neural Development in Autism Spectrum Disorder. Neuroscience. 2018;374:271–286. doi: 10.1016/j.neuroscience.2018.01.060.
    1. Horvath K., Perman J.A. Autistic disorder and gastrointestinal disease. Curr. Opin. Pediatr. 2002;14:583–587. doi: 10.1097/00008480-200210000-00004.
    1. Adams J.B., Audhya T., McDonough-Means S., Rubin R.A., Quig D., Geis E., Gehn E., Loresto M., Mitchell J., Atwood S., et al. Nutritional and metabolic status of children with autism vs. neurotypical children, and the association with autism severity. Nutr. Metab. 2011;8:34. doi: 10.1186/1743-7075-8-34.
    1. Backhed F., Ley R.E., Sonnenburg J.L., Peterson D.A., Gordon J.I. Host-bacterial mutualism in the human intestine. Science. 2005;307:1915–1920. doi: 10.1126/science.1104816.
    1. Backhed F., Roswall J., Peng Y., Feng Q., Jia H., Kovatcheva-Datchary P. Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe. 2015;5:690–703. doi: 10.1016/j.chom.2015.04.004.
    1. Sekirov I., Russell S.L., Antunes L.C., Finlay B.B. Gut microbiota in health and disease. Physiol. Rev. 2010;90:859–904. doi: 10.1152/physrev.00045.2009.
    1. Brown E.M., Sadarangani M., Finlay B.B. The role of the immune system in governing host-microbe interactions in the intestine. Nat. Immunol. 2013;14:660–667. doi: 10.1038/ni.2611.
    1. Marzano V., Mancinelli L., Bracaglia G., Del Chierico F., Vernocchi P., Di Girolamo F., Garrone S., Tchidjou Kuekou H., D’Argenio P., Dallapiccola B. “Omic” investigations of protozoa and worms for a deeper understanding of the human gut “parasitome”. PLoS Negl. Trop. Dis. 2017;11:e0005916. doi: 10.1371/journal.pntd.0005916.
    1. Jenkins T.P., Rathnayaka Y., Perera P.K., Peachey L.E., Nolan M.J., Krause L., Rajakaruna R.S., Cantacessi C. Infections by human gastrointestinal helminths are associated with changes in faecal microbiota diversity and composition. PLoS ONE. 2017;12:e0184719. doi: 10.1371/journal.pone.0184719.
    1. Leung J.M., Graham A.L., Knowles S.C.L. Parasite-microbiota interactions with the vertebrate gut: Synthesis through an ecological lens. Front. Microbiol. 2018;9:843. doi: 10.3389/fmicb.2018.00843.
    1. Chabe M., Lokmer A., Segurel L. Gut protozoa: Friends or foes of the human gut microbiota? Trends Parasitol. 2017;33:925–934. doi: 10.1016/j.pt.2017.08.005.
    1. Lopetuso L.R., Petito V., Graziani C., Schiavoni E., Paroni Sterbini F., Poscia A., Gaetani E., Franceschi F., Cammarota G., Sanguinetti M., et al. Gut Microbiota in Health, Diverticular Disease, Irritable Bowel Syndrome, and Inflammatory Bowel Diseases: Time for Microbial Marker of Gastrointestinal Disorders. Dig. Dis. 2018;36:56–65. doi: 10.1159/000477205.
    1. Diaz Heijtz R., Wang S., Anuar F., Qian Y., Björkholm B., Samuelsson A., Hibberd M.L., Forssberg H., Pettersson S. Normal gut microbiota modulates brain development and behavior. Proc. Natl. Acad. Sci. USA. 2011;108:3047–3052. doi: 10.1073/pnas.1010529108.
    1. Wang Y., Kasper L.H. The role of microbiome in central nervous system disorders. Brain Behav. Immun. 2014;38:1–12. doi: 10.1016/j.bbi.2013.12.015.
    1. Coury D.L., Ashwood P., Fasano A., Fuchs G., Geraghty M., Kaul A., Mawe G., Patterson P., Jones N.E. Gastrointestinal conditions in children with autism spectrum disorder: Developing a research agenda. Pediatrics. 2012;130(Suppl. 2):S160–S168. doi: 10.1542/peds.2012-0900N.
    1. De Angelis M., Francavilla R., Piccolo M., De Giacomo A., Gobbetti M. Autism spectrum disorders and intestinal microbiota. Gut Microbes. 2015;6:207–213. doi: 10.1080/19490976.2015.1035855.
    1. Finegold S.M., Dowd S.E., Gontcharova V., Liu C., Henley K.E., Wolcott R.D., Youn E., Summanen P.H., Granpeesheh D., Dixon D., et al. Pyrosequencing study of fecal microflora of autistic and control children. Anaerobe. 2010;16:444–453. doi: 10.1016/j.anaerobe.2010.06.008.
    1. De Angelis M., Piccolo M., Vannini L., Siragusa S., De Giacomo A., Serrazzanetti D.I., Cristofori F., Guerzoni M.E., Gobbetti M., Francavilla R. Fecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified. PLoS ONE. 2013;8:e76993. doi: 10.1371/journal.pone.0076993.
    1. Navarro F., Liu Y., Rhoads J.M. Can probiotics benefit children with autism spectrum disorders? World J. Gastroenterol. 2016;22:10093–10102. doi: 10.3748/wjg.v22.i46.10093.
    1. Mayer E.A., Padua D., Tillisch K. Altered brain-gut axis in autism: Comorbidity or causative mechanisms? Bioessays. 2014;36:933–939. doi: 10.1002/bies.201400075.
    1. Cryan J.F., Dinan T.G. Mind-altering microorganisms: The impact of the gut microbiota on brain and behaviour. Nat. Rev. Neurosci. 2012;13:701–712. doi: 10.1038/nrn3346.
    1. Borre Y.E., O’Keeffe G.W., Clarke G., Stanton C., Dinan T.G., Cryan J.F. Microbiota and neurodevelopmental windows: Implications for brain disorders. Trends Mol. Med. 2014;20:509–518. doi: 10.1016/j.molmed.2014.05.002.
    1. Fond G., Boukouaci W., Chevalier G., Regnault A., Eberl G., Hamdani N., Dickerson F., Macgregor A., Boyer L., Dargel A., et al. The “psychomicrobiotic”: Targeting microbiota in major psychiatric disorders: A systematic review. Pathol. Biol. 2015;63:35–42. doi: 10.1016/j.patbio.2014.10.003.
    1. Collins S.M., Bercik P. The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology. 2009;136:2003–2014. doi: 10.1053/j.gastro.2009.01.075.
    1. Rhee S.H., Pothoulakis C., Mayer E.A. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat. Rev. Gastroenterol. Hepatol. 2009;6:306–314. doi: 10.1038/nrgastro.2009.35.
    1. Li J., Jia H., Cai X., Zhong H., Feng Q., Sunagawa S., Arumugam M., Kultima J.R., Prifti E., Nielsen T., et al. An integrated catalog of reference genes in the human gut microbiome. Nat. Biotechnol. 2014;32:834–841. doi: 10.1038/nbt.2942.
    1. Eckburg P.B., Bik E.M., Bernstein C.N., Purdom E., Dethlefsen L., Sargent M., Relman D.A. Diversity of the human intestinal microbial flora. Science. 2005;308:1635–1638. doi: 10.1126/science.1110591.
    1. Proctor L.M. The Human Microbiome Project in 2011 and beyond. Cell Host Microbe. 2011;10:287–291. doi: 10.1016/j.chom.2011.10.001.
    1. Principi N., Esposito S. Gut microbiota and central nervous system development. J. Infect. 2016;73:536–546. doi: 10.1016/j.jinf.2016.09.010.
    1. Umbrello G., Esposito S. Microbiota and neurologic diseases: Potential effects of probiotics. J. Transl. Med. 2016;14:298. doi: 10.1186/s12967-016-1058-7.
    1. Sun J., Chang E.B. Exploring gut microbes in human health and disease: Pushing the envelope. Genes Dis. 2014;1:132–139. doi: 10.1016/j.gendis.2014.08.001.
    1. Round J.L., Mazmanian S.K. The gut microbiota shapes intestinal immune responses during health and disease. Nat. Rev. Immunol. 2009;9:313–324. doi: 10.1038/nri2515.
    1. Stilling R.M., Ryan F.J., Hoban A.E., Shanahan F., Clarke G., Claesson M.J., Dinan T.G., Cryan J.F. Microbes & neurodevelopment—Absence of microbiota during early life increases activity related transcriptional pathways in the amygdala. Brain Behav. Immun. 2015;50:209–220.
    1. Collado M.C., Rautava S., Aakko J., Isolauri E., Salminen S. Human gut colonisation may be initiated in utero by distinct microbial communities in the placenta and amniotic fluid. Sci. Rep. 2016;6:23129. doi: 10.1038/srep23129.
    1. Jiménez E., Marín M.L., Martín R., Odriozola J.M., Olivares M., Xaus J., Fernández L., Rodríguez J.M. If meconium from healthy newborns actually sterile? Res. Microbiol. 2008;159:187–193. doi: 10.1016/j.resmic.2007.12.007.
    1. Nicholson J.K., Holmes E., Kinross J., Burcelin R., Gibson G., Jia W., Pettersson S. Host-gut microbiota metabolic interactions. Science. 2012;336:1262–1267. doi: 10.1126/science.1223813.
    1. Tamburini S., Shen N., Wu H.C., Clemente J.C. The microbiome in early life: Implications for health outcomes. Nat. Med. 2016;22:713–722. doi: 10.1038/nm.4142.
    1. Kushak R.I., Buie T.M., Murray K.F., Newburg D.S., Chen C., Nestoridi E., Winter H.S. Evaluation of intestinal function in children with autism and gastrointestinal symptoms. J. Pediatr. Gastroenterol. Nutr. 2016;62:687–691. doi: 10.1097/MPG.0000000000001174.
    1. Connolly N., Anixt J., Manning P., Ping-ILin D., Marsolo K.A., Bowers K. Maternal metabolic risk factors for autism spectrum disorder-Analysis of electronic medical records and linked birth data. Autism Res. 2016;9:829–837. doi: 10.1002/aur.1586.
    1. Schultz S.T., Klonoff-Cohen H.S., Wingard D.L., Akshoomoff N.A., Macera C.A., Ji M., Bacher C. Breastfeeding, infant formula supplementation and autistic disorder: The results of a parent survey. Int. Breastfeed. 2016;1:16. doi: 10.1186/1746-4358-1-16.
    1. Azad M.B., Konya T., Maughan H., Guttman D.S., Field C.J., Chari R.S., Sears M.R., Becker A.B., Scott J.A., Kozyrskyj A.L. Gut microbiota of healthy Canadian infants: Profiles by mode of delivery and infant diet at 4 months. CMAJ. 2013;185:385–394. doi: 10.1503/cmaj.121189.
    1. Korpela K., Salonen A., Virta L.J., Kekkonen R.A., Forslund K., Bork P., de Vos W.M. Intestinal microbiome is related to lifetime antibiotic use in Finnish pre-school children. Nat. Commun. 2016;7:10410. doi: 10.1038/ncomms10410.
    1. Sherwin E., Sandhu K.V., Dinan T.G., Cryan J.F. May the Force Be with You: The Light and Dark Sides of the Microbiota–Gut–Brain Axis in Neuropsychiatry. CNS Drugs. 2016;30:1019–1041. doi: 10.1007/s40263-016-0370-3.
    1. Yassour M., Vatanen T., Siljander H., Hämäläinen A.M., Härkönen T., Ryhänen S.J., Franzosa E.A., Vlamakis H., Huttenhower C., Gevers D., et al. Natural history of the infant gut microbiome and impact of antibiotic treatments on strain-level diversity and stability. Sci. Transl. Med. 2016;8:343–381. doi: 10.1126/scitranslmed.aad0917.
    1. Ajslev T.A., Andersen C.S., Gamborg M., Sorensen T.I., Jess T. Childhood overweight after establishment of the gut microbiota: The role of delivery mode, pre-pregnancy weight and early administration of antibiotics. Int. J. Obes. 2009;35:522–529. doi: 10.1038/ijo.2011.27.
    1. Jostins L., Ripke S., Weersma R.K., Duerr R.H., McGovern D.P., Hui K.Y., Lee J.C., Schumm L.P., Sharma Y., Anderson C.A., et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119–124. doi: 10.1038/nature11582.
    1. De Magistris L., Familiari V., Pascotto A., Sapone A., Frolli A., Iardino P., Carteni M., De Rosa M., Francavilla R., Riegler G., et al. Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first-degree relatives. J. Pediatr. Gastroenterol. Nutr. 2010;5:418–424. doi: 10.1097/MPG.0b013e3181dcc4a5.
    1. De Theije C.G., Wopereis H., Ramadan M., van Eijndthoven T., Lambert J., Knol J., Garssen J., Kraneveld A.D., Oozeer R. Altered gut microbiota and activity in a murine model of autism spectrum disorders. Brain Behav. Immun. 2014;37:197–206. doi: 10.1016/j.bbi.2013.12.005.
    1. Finegold S.M., Downes J., Summanen P.H. Microbiology of regressive autism. Anaerobe. 2012;18:260–262. doi: 10.1016/j.anaerobe.2011.12.018.
    1. Kang D.W., Park J.G., Ilhan Z.E., Wallstrom G., LaBaer J., Adams J.B., Krajmalnik-Brown R. Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children. PLoS ONE. 2013;8:e68322. doi: 10.1371/journal.pone.0068322.
    1. Finegold S.M., Molitoris D., Song Y., Liu C., Vaisanen M.L., Bolte E., McTeague M., Sandler R., Wexler H., Marlowe E.M., et al. Gastrointestinal microflora studies in late-onset autism. Clin. Infect. Dis. 2002;35:S6–S16. doi: 10.1086/341914.
    1. Finegold S.M. Desulfovibrio species are potentially important in regressive autism. Med. Hypotheses. 2011;77:270–274. doi: 10.1016/j.mehy.2011.04.032.
    1. Tomova A., Husarova V., Lakatosova S., Bakos J., Vlkova B., Babinska K., Ostatnikova D. Gastrointestinal microbiota in children with autism in Slovakia. Physiol. Behav. 2015;138:179–187. doi: 10.1016/j.physbeh.2014.10.033.
    1. Emanuele E., Orsi P., Boso M., Broglia D., Brondino N., Barale F., di Nemi S.U., Politi P. Low-grade endotoxemia in patients with severe autism. Neurosci. Lett. 2010;471:162–165. doi: 10.1016/j.neulet.2010.01.033.
    1. Williams B.L., Hornig M., Parekh T., Ian Lipkin W. Application of novel PCR-based methods for detection, quantitation, and phylogenetic characterization of Sutterella species in intestinal biopsy samples from children with autism and gastrointestinal disturbances. MBio. 2012;3:e00261-11. doi: 10.1128/mBio.00261-11.
    1. Wang L., Christophersen C.T., Sorich M.J., Gerber J.P., Angley M.T., Conlon M.A. Elevated fecal short chain fatty acid and ammonia concentrations in children with autism spectrum disorder. Dig. Dis. Sci. 2012;57:2096–2102. doi: 10.1007/s10620-012-2167-7.
    1. Song Y., Liu C., Finegold S.M. Real-time PCR quantitation of clostridia in feces of autistic children. Appl. Environ. Microbiol. 2004;70:6459–6465. doi: 10.1128/AEM.70.11.6459-6465.2004.
    1. Parracho H.M.R.T., Bingham M.O., Gibson G.R., McCartney A.L. Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children. J. Med. Microbiol. 2005;54:987–991. doi: 10.1099/jmm.0.46101-0.
    1. Ding H.T., Taur Y., Walkup J.T. Gut Microbiota and Autism: Key Concepts and Findings. J. Autism Dev. Disord. 2017;47:480–489. doi: 10.1007/s10803-016-2960-9.
    1. Sandler R.H., Finegold S.M., Bolte E.R., Buchanan C.P., Maxwell A.P., Vaisanen M.L., Wexler H.M. Short term beneit from oral vancomycin treatment of regressive-onset autism. J. Child Neurol. 2000;15:429–435. doi: 10.1177/088307380001500701.
    1. Yang Y., Tian J., Yang B. Targeting gut microbiome: A novel and potential therapy for autism. Life Sci. 2018;194:111–119. doi: 10.1016/j.lfs.2017.12.027.
    1. Finegold S.M. Therapy and epidemiology of autism-clostridial spores as key elements. Med. Hypotheses. 2008;70:508–511. doi: 10.1016/j.mehy.2007.07.019.
    1. Argou-Cardozo I., Zeidán-Chuliá F. Clostridium Bacteria and Autism Spectrum Conditions: A Systematic Review and Hypothetical Contribution of Environmental Glyphosate Levels. Med. Sci. 2018;6:29. doi: 10.3390/medsci6020029.
    1. Kushak R.I., Winter H.S., Buie T.M., Cox S.B., Phillips C.D., Ward N.L. Analysis of the Duodenal Microbiome in Autistic Individuals: Association with Carbohydrate Digestion. J. Pediatr. Gastroenterol. Nutr. 2017;64:e110–e116. doi: 10.1097/MPG.0000000000001458.
    1. Qiao Y., Wu M., Feng Y., Zhou Z., Chen L., Chen F. Alterations of oral microbiota distinguish children with autism spectrum disorders from healthy controls. Sci. Rep. 2018;8:1597. doi: 10.1038/s41598-018-19982-y.
    1. Arumugam M., Raes J., Pelletier E., Le Paslier D., Yamada T., Mende D.R., Fernandes G.R., Tap J., Bruls T., Batto J.M., et al. Enterotypes of the human gut microbiome. Nature. 2011;506:516. doi: 10.1038/nature13075.
    1. Kantarcioglu A.S., Kiraz N., Aydin A. Microbiota-gut-brain axis: Yeast species isolated from stool samples of children with suspected or diagnosed autism spectrum disorders and in vitro susceptibility against nystatin and fluconazole. Mycopathologia. 2016;181:1–7. doi: 10.1007/s11046-015-9949-3.
    1. Iovene M.R., Bombace F., Maresca R., Sapone A., Iardino P., Picardi A., Marotta R., Schiraldi C., Siniscalco D., Serra N., et al. Intestinal dysbiosis and yeast isolation in stool of subjects with autism spectrum disorders. Mycopathologia. 2017;182:349–363. doi: 10.1007/s11046-016-0068-6.
    1. Strati F., Cavalieri D., Albanese D., De Felice C., Donati C., Hayek J., Jousson O., Leoncini S., Renzi D., Calabrò A., et al. New evidences on the altered gut microbiota in autism spectrum disorders. Microbiome. 2017;5:24. doi: 10.1186/s40168-017-0242-1.
    1. Claesson M.J., Cusack S., O’Sullivan O., Greene-Diniz R., de Weerd H., Flannery E., Marchesi J.R., Falush D., Dinan T., Fitzgerald G., et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc. Natl. Acad. Sci. USA. 2011;108(Suppl. 1):4586–4591. doi: 10.1073/pnas.1000097107.
    1. Wang L.W., Tancredi D.J., Thomas D.W. The prevalence of gastrointestinal problems in children across the United States with autism spectrum disorders from families with multiple affected members. J. Dev. Behav. Pediatr. 2011;32:351–360. doi: 10.1097/DBP.0b013e31821bd06a.
    1. Mazurek M.O., Vasa R.A., Kalb L.G., Kanne S.M., Rosenberg D., Keefer A., Murray D.S., Freedman B., Lowery L.A. Anxiety, sensory over-responsivity, and gastrointestinal problems in children with autism spectrum disorders. J. Abnorm. Child Psychol. 2013;41:165–176. doi: 10.1007/s10802-012-9668-x.
    1. McElhanon B.O., McCracken C., Karpen S., Sharp W.G. Gastrointestinal symptoms in autism spectrum disorder: A meta-analysis. Pediatrics. 2014;133:872–883. doi: 10.1542/peds.2013-3995.
    1. De Theije C.G., Wu J., da Silva S.L., Kamphuis P.J., Garssen J., Korte S.M. Pathways underlying the gut-to-brain connection in autism spectrum disorders as future targets for disease management. Eur. J. Pharmacol. 2011;668(Suppl. 1):S70–S80. doi: 10.1016/j.ejphar.2011.07.013.
    1. Rose D.R., Yang H., Serena G., Sturgeon C., Ma B., Careaga M., Hughes H.K., Angkustsiri K., Rose M., Hertz-Picciotto I., et al. Differential immune responses and microbiota profiles in children with autism spectrum disorders and co-morbid gastrointestinal symptoms. Brain Behav. Immun. 2018;70:354–368. doi: 10.1016/j.bbi.2018.03.025.
    1. Walker S.J., Fortunato J., Gonzalez L.G., Krigsman A. Identification of unique gene expression profile in children with regressive autism spectrum disorder (ASD) and ileocolitis. PLoS ONE. 2013;8:e58058. doi: 10.1371/journal.pone.0058058.
    1. Fernell E., Fagerberg U.L., Hellström P.M. No evidence for a clear link between active intestinal inflammation and autism based on analyses of faecal calprotectin and rectal nitric oxide. Acta Paediatr. 2007;96:1076–1079. doi: 10.1111/j.1651-2227.2007.00298.x.
    1. Boso M., Emanuele E., Minoretti P., Arra M., Politi P., Ucelli di Nemi S., Barale F. Alterations of circulating endogenous secretory RAGE and S100A9 levels indicating dysfunction of the AGE-RAGE axis in autism. Neurosci. Lett. 2006;410:169–173. doi: 10.1016/j.neulet.2006.08.092.
    1. Vuong H.E., Hsiao E.Y. Emerging Roles for the Gut Microbiome in Autism Spectrum Disorder. Biol. Psychiatry. 2017;81:411–423. doi: 10.1016/j.biopsych.2016.08.024.
    1. Viggiano D., Ianiro G., Vanella G., Bibbò S., Bruno G., Simeone G., Mele G. Gut barrier in health and disease: Focus on childhood. Eur. Rev. Med. Pharmacol. Sci. 2015;9:1077–1085.
    1. Ashwood P., Anthony A., Pellicer A.A., Torrente F., Walker-Smith J.A., Wakefield A.J. Intestinal lymphocyte populations in children with regressive autism: Evidence for extensive mucosal immunopathology. J. Clin. Immunol. 2003;23:504–517. doi: 10.1023/B:.
    1. Ashwood P., Anthony A., Torrente F., Wakefield A.J. Spontaneous mucosal lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms: Mucosal immune activation and reduced counter regulatory interleukin-10. J. Clin. Immunol. 2004;24:664–673. doi: 10.1007/s10875-004-6241-6.
    1. Torrente F., Ashwood P., Day R., Machado N., Furlano R.I., Anthony A., Davies S.E., Wakefield A.J., Thomson M.A., Walker-Smith J.A., et al. Small intestinal enteropathy with epithelial IgG and complement deposition in children with regressive autism. Mol. Psychiatry. 2002;7:375–382. doi: 10.1038/sj.mp.4001077.
    1. Ashwood P., Wakefield A.J. Immune activation of peripheral blood and mucosal CD3+ lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms. J. Neuroimmunol. 2006;73:126–134. doi: 10.1016/j.jneuroim.2005.12.007.
    1. Hsiao E.Y., McBride S.W., Hsien S., Sharon G., Hyde E.R., McCue T., Codelli J.A., Chow J., Reisman S.E., Petrosino J.F., et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell. 2013;155:1451–1463. doi: 10.1016/j.cell.2013.11.024.
    1. Ashwood P., Krakowiak P., Hertz-Picciotto I., Hansen R., Pessah I., Van de Water J. Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. Brain Behav. Immun. 2011;25:40–45. doi: 10.1016/j.bbi.2010.08.003.
    1. Onore C., Careaga M., Ashwood P. The role of immune dysfunction in the pathophysiology of autism. Brain Behav. Immun. 2012;26:383–392. doi: 10.1016/j.bbi.2011.08.007.
    1. Pusponegoro H.D., Ismael S., Sastroasmoro S., Firmansyah A., Vandenplas Y. Maladaptive Behavior and Gastrointestinal Disorders in Children with Autism Spectrum Disorder. Pediatr. Gastroenterol. Hepatol. Nutr. 2015;18:230–237. doi: 10.5223/pghn.2015.18.4.230.
    1. Dalton N., Chandler S., Turner C., Charman T., Pickles A., Loucas T., Simonoff E., Sullivan P., Baird G. Gut permeability in autism spectrum disorders. Autism Res. 2014;7:305–313. doi: 10.1002/aur.1350.
    1. Souza N.C., Mendonca J.N., Portari G.V., Jordao Junior A.A., Marchini J.S., Chiarello P.G. Intestinal permeability and nutritional status in developmental disorders. Altern. Ther. Health Med. 2012;18:19–24.
    1. Ashwood P., Enstrom A., Krakowiak P., Hertz-Picciotto I., Hansen R.L., Croen L.A., Ozonoff S., Pessah I.N., Van de Water J. Decreased transforming growth factor beta1 in autism: A potential link between immune dysregulation and impairment in clinical behavioral outcomes. J. Neuroimmunol. 2008;204:149–153. doi: 10.1016/j.jneuroim.2008.07.006.
    1. Mayer E.A. Gut feelings: The emerging biology of gut-brain communication. Nat. Rev. Neurosci. 2011;12:453–466. doi: 10.1038/nrn3071.
    1. Yarandi S.S., Peterson D.A., Treisman G.J., Moran T.H., Pasricha P.J. Modulatory effects of gut microbiota on the central nervous system: How gut could play a role in neuropsychiatric health and diseases. J. Neurogastroenterol. Motil. 2016;22:201–212. doi: 10.5056/jnm15146.
    1. Abreu M.T. Toll-like receptor signalling in the intestinal epithelium: How bacterial recognition shapes intestinal function. Nat. Rev. Immunol. 2010;10:131–144. doi: 10.1038/nri2707.
    1. Bravo J.A., Forsythe P., Chew M.V., Escaravage E., Savignac H.M., Dinan T.G., Bienenstock J., Cryan J.F. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc. Natl. Acad. Sci. USA. 2011;108:16050–16055. doi: 10.1073/pnas.1102999108.
    1. McVey Neufeld K.A., Mao Y.K., Bienenstock J., Foster J.A., Kunze W.A. The microbiome is essential for normal gut intrinsic primary afferent neuron excitability in the mouse. Neurogastroenterol. Motil. 2013;25:183–188. doi: 10.1111/nmo.12049.
    1. O’Mahony S.M., Clarke G., Borre Y.E., Dinan T.G., Cryan J.F. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. Behav. Brain Res. 2015;277:32–48. doi: 10.1016/j.bbr.2014.07.027.
    1. Israelyan N., Margolis K.G. Serotonin as a Link Between the Gut-Brain-Microbiome Axis in Autism Spectrum Disorders. Pharmacol. Res. 2018;132:1–6. doi: 10.1016/j.phrs.2018.03.020.
    1. Gaspar P., Cases O., Maroteaux L. The developmental role of serotonin: News from mouse molecular genetics. Nat. Rev. Neurosci. 2003;4:1002–1012. doi: 10.1038/nrn1256.
    1. Anderson G.M., Freedman D.X., Cohen D.J., Volkmar F.R., Hoder E.L., McPhedran P., Minderaa R.B., Hansen C.R., Young J.G. Whole blood serotonin in autistic and normal subjects. J. Child Psychol. Psychiatry. 1987;28:885–900. doi: 10.1111/j.1469-7610.1987.tb00677.x.
    1. Hanley H.G., Stahl S.M., Freedman D.X. Hyperserotonemia and amine metabolites in autistic and retarded children. Arch. Gen. Psychiatry. 1977;34:521–531. doi: 10.1001/archpsyc.1977.01770170031002.
    1. Marler S., Ferguson B.J., Lee E.B., Peters B., Williams K.C., McDonnell E., Macklin E.A., Levitt P., Gillespie C.H., Anderson G.M., et al. Brief report: Whole blood serotonin levels and gastrointestinal symptoms in autism spectrum disorder. J. Autism Dev. Disord. 2016;46:1124–1130. doi: 10.1007/s10803-015-2646-8.
    1. Minderaa R.B., Anderson G.M., Volkmar F.R., Akkerhuis G.W., Cohen D.J. Urinary 5-hydroxyindoleacetic acid and whole blood serotonin and tryptophan in autistic and normal subjects. Biol. Psychiatry. 1987;22:933–940. doi: 10.1016/0006-3223(87)90002-3.
    1. Mulder E.J., Anderson G.M., Kemperman R.F., Oosterloo-Duinkerken A., Minderaa R.B., Kema I.P. Urinary excretion of 5-hydroxyindoleacetic acid, serotonin and 6-sulphatoxymelatonin in normoserotonemic and hyperserotonemic autistic individuals. Neuropsychobiolog. 2010;61:27–32. doi: 10.1159/000258640.
    1. Meyza K.Z., Defensor E.B., Jensen A.L., Corley M.J., Pearson B.L., Pobbe R.L., Bolivar V.J., Blanchard D.C., Blanchard R.J. The BTBR T+ tf/J mouse model for autism spectrum disorders-in search of biomarkers. Behav. Brain Res. 2013;251:25–34. doi: 10.1016/j.bbr.2012.07.021.
    1. Golubeva A.V., Joyce S.A., Moloney G., Burokas A., Sherwin E., Arboleya S., Flynn I., Khochanskiy D., Moya-Pérez A., Peterson V., et al. Microbiota-related Changes in Bile Acid & Tryptophan Metabolism are Associated with Gastrointestinal Dysfunction in a Mouse Model of Autism. EBioMedicine. 2017;24:166–178.
    1. Luna R.A., Oezguen N., Balderas M., Venkatachalam A., Runge J.K., Versalovic J., Veenstra-VanderWeele J., Anderson G.M., Savidge T., Williams K.C. Distinct Microbiome-Neuroimmune Signatures Correlate with Functional Abdominal Pain in Children with Autism Spectrum Disorder. Cell. Mol. Gastroenterol. Hepatol. 2017;3:218–230. doi: 10.1016/j.jcmgh.2016.11.008.
    1. Chugani D.C., Muzik O., Behen M., Rothermel R., Janisse J.J., Lee J., Chugani H.T. Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. Ann. Neurol. 1999;45:287–295. doi: 10.1002/1531-8249(199903)45:3<287::AID-ANA3>;2-9.
    1. Kolevzon A., Newcorn J.H., Kryzak L., Chaplin W., Watner D., Hollander E., Smith C.J., Cook E.H., Jr., Silverman J.M. Relationship between whole blood serotonin and repetitive behaviors in autism. Psychiatry Res. 2010;175:274–276. doi: 10.1016/j.psychres.2009.02.008.
    1. Muller C.L., Anacker A.M.J., Veenstra-VanderWeele J. The serotonin system in autism spectrum disorder: From biomarker to animal models. Neuroscience. 2016;321:24–41. doi: 10.1016/j.neuroscience.2015.11.010.
    1. Macfabe D.F. Short-chain fatty acid fermentation products of the gut microbiome: Implications in autism spectrum disorders. Microb. Ecol. Health Dis. 2012;23:19260. doi: 10.3402/mehd.v23i0.19260.
    1. Altieri L., Neri C., Sacco R., Curatolo P., Benvenuto A., Muratori F., Santocchi E., Bravaccio C., Lenti C., Saccani M., et al. Urinary p-cresol is elevated in small children with severe autism spectrum disorder. Biomarkers. 2011;16:252–260. doi: 10.3109/1354750X.2010.548010.
    1. Persico A.M., Napolioni V. Urinary p-cresol in autism spectrum disorder. Neurotoxicol. Tertol. 2013;36:82–90. doi: 10.1016/j.ntt.2012.09.002.
    1. Gabriele S., Sacco R., Cerullo S., Neri C., Urbani A., Tripi G., Malvy J., Barthelemy C., Bonnet-Brihault F., Persico A.M. Urinary p-cresol is elevated in young French children with autism spectrum disorder: A replication study. Biomarkers. 2014;19:463–470. doi: 10.3109/1354750X.2014.936911.
    1. Al-Lahham S.H., Peppelenbosch M.P., Roelofsen H., Vonk R.J., Venema K. Biological effects of propionic acid in humans; metabolism, potential applications and underlying mechanisms. Biochim. Biophys. Acta. 2010;1801:1175–1183. doi: 10.1016/j.bbalip.2010.07.007.
    1. MacFabe D.F. Enteric short-chain fatty acids: Microbial messengers of metabolism, mitochondria, and mind: Implications in autism spectrum disorders. Microb. Ecol. Health Dis. 2015;26:28177. doi: 10.3402/mehd.v26.28177.
    1. DeCastro M., Nankova B.B., Shah P., Patel P., Mally P.V., Mishra R., La Gamma E.F. Short chain fatty acids regulate tyrosine hydroxylase gene expression through a cAMP-dependent signaling pathway. Brain Res. Mol. Brain Res. 2005;142:28–38. doi: 10.1016/j.molbrainres.2005.09.002.
    1. Shultz S.R., Macfabe D.F., Martin S., Jackson J., Taylor R., Boon F., Ossenkopp K.P., Cain D.P. Intracerebroventricular injections of the enteric bacterial metabolic product propionic acid impair cognition and sensorimotor ability in the Long-Evans rat: Further development of a rodent model of autism. Behav. Brain Res. 2009;200:33–41. doi: 10.1016/j.bbr.2008.12.023.
    1. Shultz S.R., MacFabe D.F., Ossenkopp K.P., Scratch S., Whelan J., Taylor R., Cain D.P. Intracerebroventricular injection of propionic acid, an enteric bacterial metabolic end-product, impairs social behavior in the rat: Implications for an animal model of autism. Neuropharmacolog. 2008;54:901–911. doi: 10.1016/j.neuropharm.2008.01.013.
    1. Thomas R.H., Meeking M.M., Mepham J.R., Tichenoff L., Possmayer F., Liu S., MacFabe D.F. The enteric bacterial metabolite propionic acid alters brain and plasma phospholipid molecular species: Further development of a rodent model of autism spectrum disorders. J. Neuroinflamm. 2012;9:153. doi: 10.1186/1742-2094-9-153.
    1. MacFabe D.F., Cain D.P., Rodriguez-Capote K., Franklin A.E., Hoffman J.E., Boon F., Taylor A.R., Kavaliers M., Ossenkopp K.P. Neurobiological effects of intraventricular propionic acid in rats: Possible role of short chain fatty acids on the pathogenesis and characteristics of autism spectrum disorders. Behav. Brain Res. 2007;176:149–169. doi: 10.1016/j.bbr.2006.07.025.
    1. MacFabe D.F., Cain N.E., Boon F., Ossenkopp K.P., Cain D.P. Effects of the enteric bacterial metabolic product propionic acid on object-directed behavior, social behavior, cognition, and neuroinflammation in adolescent rats: Relevance to autism spectrum disorder. Behav. Brain Res. 2011;217:47–54. doi: 10.1016/j.bbr.2010.10.005.
    1. Hong J., Jia Y., Pan S., Jia L., Li H., Han Z., Cai D., Zhao R. Butyrate alleviates high fat diet-induced obesity through activation of adiponectin-mediated pathway and stimulation of mitochondrial function in the skeletal muscle of mice. Oncotarget. 2016;7:56071–56082. doi: 10.18632/oncotarget.11267.
    1. Govindarajan N., Agis-Balboa R.C., Walter J., Sananbenesi F., Fischer A. Sodium butyrate improves memory function in an Alzheimer’s disease mouse model when administered at an advanced stage of disease progression. J. Alzheimer Dis. 2011;26:187–197. doi: 10.3233/JAD-2011-110080.
    1. Sun J., Wang F., Hong G., Pang M., Xu H., Li H., Tian F., Fang R., Yao Y., Liu J. Antidepressant-like effects of sodium butyrate and its possible mechanisms of action in mice exposed to chronic unpredictable mild stress. Neurosci. Lett. 2016;618:159–166. doi: 10.1016/j.neulet.2016.03.003.
    1. Sun J., Ling Z., Wang F., Chen W., Li H., Jin J., Zhang H., Pang M., Yu J., Liu J. Clostridium butyricum pretreatment attenuates cerebral ischemia/reperfusion injury in mice via anti-oxidation and anti-apoptosis. Neurosci. Lett. 2016;613:30–35. doi: 10.1016/j.neulet.2015.12.047.
    1. Rose S., Bennuri S.C., Davis J.E., Wynne R., Slattery J.C., Tippett M., Delhey L., Melnyk S., Kahler S.G., MacFabe D.F., et al. Butyrate enhances mitochondrial function during oxidative stress in cell lines from boys with autism. Transl. Psychiatry. 2018;8:42. doi: 10.1038/s41398-017-0089-z.
    1. Takuma K., Hara Y., Kataoka S., Kawanai T., Maeda Y., Watanabe R., Takano E., Hayata-Takano A., Hashimoto H., Ago Y., et al. Chronic treatment with valproic acid or sodium butyrate attenuates novel object recognition deficits and hippocampal dendritic spine loss in a mouse model of autism. Pharmacol. Biochem. Behav. 2014;126:43–49. doi: 10.1016/j.pbb.2014.08.013.
    1. Kratsman N., Getselter D., Elliott E. Sodium butyrate attenuates social behavior deficits and modifies the transcription of inhibitory/excitatory genes in the frontal cortex of an autism model. Neuropharmacolog. 2016;102:136–145. doi: 10.1016/j.neuropharm.2015.11.003.
    1. Ming X., Stein T.P., Barnes V., Rhodes N., Guo L. Metabolic perturbance in autism spectrum disorders: A metabolomics study. J. Proteome Res. 2012;11:5856–5862. doi: 10.1021/pr300910n.
    1. Shimmura C., Suda S., Tsuchiya K.J., Hashimoto K., Ohno K., Matsuzaki H., Iwata K., Matsumoto K., Wakuda T., Kameno Y., et al. Alteration of plasma glutamate and glutamine levels in children with high-functioning autism. PLoS ONE. 2011;6:e25340. doi: 10.1371/journal.pone.0025340.
    1. Noto A., Fanos V., Barberini L., Grapov D., Fattuoni C., Zaffanello M., Casanova A., Fenu G., De Giacomo A., De Angelis M., et al. The urinary metabolomics profile of an Italian autistic children population and their unaffected siblings. J. Matern. Fetal Neonatal Med. 2014;27(Suppl. 2):46–52. doi: 10.3109/14767058.2014.954784.
    1. Shaw W. Increased urinary excretion of a 3-(3-hydroxyphenyl)-3-hydroxypropionic acid (HPHPA), an abnormal phenylalanine metabolite of Clostridia spp. in the gastrointestinal tract, in urine samples from patients with autism and schizophrenia. Nutr. Neurosci. 2010;13:135–143. doi: 10.1179/147683010X12611460763968.
    1. Santocchi E., Guiducci L., Fulceri F., Billeci L., Buzzigoli E., Apicella F., Calderoni S., Grossi E., Morales M.A., Muratori F. Gut to brain interaction in Autism Spectrum Disorders: A randomized controlled trial on the role of probiotics on clinical, biochemical and neurophysiological parameters. BMC Psychiatry. 2016;16:183. doi: 10.1186/s12888-016-0887-5.
    1. Doenyas C. Dietary interventions for autism spectrum disorder: New perspectives from the gut-brain axis. Physiol. Behav. 2018;194:577–582. doi: 10.1016/j.physbeh.2018.07.014.
    1. Liu J., Liu X., Xiong X.Q., Yang T., Cui T., Hou N.L., Lai X., Liu S., Guo M., Liang X.H., et al. Effect of vitamin A supplementation on gut microbiota in children with autism spectrum disorders—A pilot study. BMC Microbiol. 2017;17:204. doi: 10.1186/s12866-017-1096-1.
    1. Fallon J. Could one of the most widely prescribed antibiotics amoxicillin/clavulanate “Augmentin” be a risk factor for autism? Med. Hypotheses. 2005;64:312–315. doi: 10.1016/j.mehy.2004.06.023.
    1. Niehus R., Lord C. Early medical history of children with autism spectrum disorders. J. Dev. Behav. Pediatr. 2006;27(Suppl. 2):S120–S127. doi: 10.1097/00004703-200604002-00010.
    1. Atladóttir H.Ó., Henriksen T.B., Schendel D.E., Parner E.T. Autism after infection, febrile episodes, and antibiotic use during pregnancy: An exploratory study. Pediatrics. 2012;130:e1447–e1454. doi: 10.1542/peds.2012-1107.
    1. Pineiro M., Asp N.G., Reid G., Macfarlane S., Morelli L., Brunser O., Tuohy K. FAO technical meeting on prebiotics. J. Clin. Gastroenterol. 2008;42:S156–S159. doi: 10.1097/MCG.0b013e31817f184e.
    1. Grimaldi R., Cela D., Swann J.R., Vulevic J., Gibson G.R., Tzortzis G., Costabile A. In vitro fermentation of B-GOS: Impact on faecal bacterial populations and metabolic activity in autistic and non-autistic children. FEMS Microbiol. Ecol. 2017;93:fiw233. doi: 10.1093/femsec/fiw233.
    1. Schmidt K., Cowen P.J., Harmer C.J., Tzortzis G., Errington S., Burnet P.W.J. Prebiotic intake reduces the waking cortisol response and alters emotional bias in healthy volunteers. Psychopharmacolog. 2015;232:1793–1801. doi: 10.1007/s00213-014-3810-0.
    1. Lavasani S., Dzhambazov B., Nouri M., Fak F., Buske S., Molin G., Thorlacius H., Alenfall J., Jeppsson B., Weström B. A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells. PLoS ONE. 2010;5:e9009. doi: 10.1371/journal.pone.0009009.
    1. Kwon H.K., Kim G.C., Kim Y., Hwang W., Jash A., Sahoo A., Kim J.E., Nam J.H., Im S.H. Amelioration of experimental autoimmune encephalomyelitis by probiotic mixture is mediated by a shift in T helper cell immune response. Clin. Immunol. 2013;146:217–227. doi: 10.1016/j.clim.2013.01.001.
    1. Chae C.S., Kwon H.K., Hwang J.S., Kim J.E., Im S.H. Prophylactic effect of probiotics on the development of experimental autoimmune myasthenia gravis. PLoS ONE. 2012;7:e52119. doi: 10.1371/journal.pone.0052119.
    1. Savignac H.M., Tramullas M., Kiely B., Dinan T.G., Cryan J.F. Bifidobacteria modulate cognitive processes in an anxious mouse strain. Behav. Brain Res. 2015;287:59–72. doi: 10.1016/j.bbr.2015.02.044.
    1. Desbonnet L., Garrett L., Clarke G., Bienenstock J., Dinan T.G. The probiotic Bifidobacteria infantis: An assessment of potential antidepressant properties in the rat. J. Psychiatry Res. 2008;43:164–174. doi: 10.1016/j.jpsychires.2008.03.009.
    1. Ushakova G., Fed’kiv O., Prykhod’ko O., Pierzynowski S., Kruszewska D. The effect of long-term lactobacilli (lactic acid bacteria) enteral treatment on the central nervous system of growing rats. J. Nutr. Biochem. 2009;20:677–684. doi: 10.1016/j.jnutbio.2008.06.010.
    1. Tillisch K., Labus J., Kilpatrick L., Jiang Z., Stains J., Ebrat B., Guyonnet D., Legrain-Raspaud S., Trotin B., Naliboff B., et al. Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterolog. 2013;144:1394–1401. doi: 10.1053/j.gastro.2013.02.043.
    1. Rao A.V., Bested A.C., Beaulne T.M., Katzman M.A., Iorio C., Berardi J.M., Logan A.C. A randomized, double-blind, placebocontrolled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut Pathog. 2009;1:6. doi: 10.1186/1757-4749-1-6.
    1. Bagdasarian N., Rao K., Malani P.N. Diagnosis and treatment of Clostridium difficile in adults a systematic review. JAMA. 2015;313:398–408. doi: 10.1001/jama.2014.17103.
    1. Moayyedi P., Quigley E.M.M., Lacy B.E., Lembo A.J., Saito Y.A., Schiller L.R., Soffer E.E., Spiegel B.M.R., Ford A.C. The effect of fiber supplementation on irritable bowel syndrome: A systematic review and meta-analysis. Am. J. Gastroenterol. 2014;109:1367–1374. doi: 10.1038/ajg.2014.195.
    1. Kang D.W., Adams J.B., Gregory A.C., Borody T., Chittick L., Fasano A., Khoruts A., Geis E., Maldonado J., McDonough-Means S., et al. Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: An open-label study. Microbiome. 2017;5:10. doi: 10.1186/s40168-016-0225-7.
    1. Estruch R., Ros E., Salas-Salvado J., Covas M.I., Corella D., Aros F., Gomez-Gracia E., Ruiz-Gutierrez V., Fiol M., Lapetra J. Primary prevention of cardiovascular disease with a mediterranean diet. N. Engl. J. Med. 2013;36:1279–1290. doi: 10.1056/NEJMoa1200303.
    1. Toribio-Mateas M. Harnessing the power of microbiome assessment tools as part of neuroprotective nutrition and lifestyle medicine interventions. Microorganisms. 2018;6:35. doi: 10.3390/microorganisms6020035.
    1. Guasch-Ferre M., Hu F.B., Ruiz-Canela M., Bullo M., Toledo E., Wang D.D., Corella D., Gomez-Gracia E., Fiol M., Estruch R. Plasma metabolites from choline pathway and risk of cardiovascular disease in the predimed (prevention with mediterranean diet) study. J. Am. Heart Assoc. 2017;6:e006524. doi: 10.1161/JAHA.117.006524.
    1. De Filippis F., Pellegrini N., Vannini L., Jeffery I.B., La Storia A., Laghi L., Serrazanetti D.I., Di Cagno R., Ferrocino I., Lazzi C. High-level adherence to a mediterranean diet beneficially impacts the gut microbiota and associated metabolome. Gut. 2016;65:1812–1821. doi: 10.1136/gutjnl-2015-309957.
    1. Sanctuary M.R., Kain J.N., Angkustsiri K., German J.B. Dietary Considerations in Autism Spectrum Disorders: The Potential Role of Protein Digestion and Microbial Putrefaction in the Gut-Brain Axis. Front. Nutr. 2018;5:40. doi: 10.3389/fnut.2018.00040.
    1. Reichelt K.L., Tveiten D., Knivsberg A.M., Bronstad G. Peptides’ role in autism with emphasis on exorphins. Microb. Ecol. Health Dis. 2012;23:18958. doi: 10.3402/mehd.v23i0.18958.
    1. Reichelt K.L., Knivsberg A.M. The possibility and probability of a gut-to-brain connection in autism. Ann. Clin. Psychiatry. 2009;21:205–211.
    1. Marì-Bauset S., Zazpe I., Mari-Sanchis A., Llopis-Gonz_alez A., Morales-Suarez-Varela M. Evidence of the gluten-free and casein-free diet in autism spectrum disorders: A systematic review. J. Child Neurol. 2014;29:1718–1727. doi: 10.1177/0883073814531330.
    1. Campbell-McBride N. Gut and psycholoy syndrome. J. Orthomol. Med. 2008;23:13–23.
    1. Knivsberg A., Reichelt K., Høien T., Nødland M. A randomised, controlled study of dietary intervention in autistic syndromes. Nutr. Neurosci. 2002;5:251–261. doi: 10.1080/10284150290028945.
    1. Whiteley P., Haracopos D., Knivsberg A.M., Reichelt K.L., Parlar S., Jacobsen J., Seim A., Pedersen L., Schondel M., Shattock P. The ScanBrit randomised, controlled, single-blind study of a gluten- and casein-free dietary intervention for children with autism spectrum disorders. Nutr. Neurosci. 2010;13:87–100. doi: 10.1179/147683010X12611460763922.
    1. Pennesi C.M., Klein L.C. Effectiveness of the gluten-free, casein-free diet for children diagnosed with autismspectrumdisorder: Based on parental report. Nutr. Neurosci. 2012;15:85–91. doi: 10.1179/1476830512Y.0000000003.
    1. Ruskin D.N., Svedova J., Cote J.L., Sandau U., Rho J.M., Kawamura M., Jr., Masino S.A. Ketogenic diet improves core symptoms of autism in BTBR mice. PLoS ONE. 2013;8:e65021. doi: 10.1371/journal.pone.0065021.
    1. Castro K., Faccioli L.S., Baronio D., Gottfried C., Perry I.S., dos Santos Riesgo R. Effect of a ketogenic diet on autism spectrum disorder: A systematic review. Res. Autism Spectr. Disord. 2015;20:31–38. doi: 10.1016/j.rasd.2015.08.005.
    1. Liu Y., Fatheree N.Y., Mangalat N., Rhoads J.M. Human-derived probiotic Lactobacillus reuteri strains differentially reduce intestinal inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 2010;299:G1087–G1096. doi: 10.1152/ajpgi.00124.2010.
    1. Jonkers D., Penders J., Masclee A., Pierik M. Probiotics in the management of inflammatory bowel disease: A systematic review of intervention studies in adult patients. Drugs. 2012;72:803–823. doi: 10.2165/11632710-000000000-00000.
    1. Zhang Y., Li L., Guo C., Mu D., Feng B., Zuo X., Li Y. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: A meta-analysis. BMC Gastroenterol. 2016;16:62. doi: 10.1186/s12876-016-0470-z.
    1. Giannetti E., Staiano A. Probiotics for Irritable Bowel Syndrome: Clinical Data in Children. J. Pediatr. Gastroenterol. Nutr. 2016;63(Suppl. 1):S25–S26.
    1. Li M., Fallin M.D., Riley A., Landa R., Walker S.O., Silverstein M., Caruso D., Pearson C., Kiang S., Dahm J.L., et al. The association of maternal obesity and diabetes with autism and other developmental disabilities. Pediatrics. 2016;137:e20152206. doi: 10.1542/peds.2015-2206.
    1. Nahum Sacks K., Friger M., Shoham-Vardi I., Abokaf H., Spiegel E., Sergienko R., Landau D., Sheiner E. Prenatal exposure to gestational diabetes mellitus as an independent risk factor for long-term neurologic morbidity of the offspring. Am. J. Obstet. Gynecol. 2016;214:S48–S49. doi: 10.1016/j.ajog.2015.10.086.
    1. Buffington S.A., Di Prisco G.V., Auchtung T.A., Ajami N.J., Petrosino J.F., Costa-Mattioli M. Microbial reconstitution reverses maternal diet-induced social and synaptic deficits in offspring. Cell. 2016;165:1762–1775. doi: 10.1016/j.cell.2016.06.001.
    1. Donaldson Z.R., Young L.J. Oxytocin, vasopressin and the neurogenics of sociality. Science. 2008;322:900–904. doi: 10.1126/science.1158668.
    1. El-Ansary A., Bacha A.B., Bjørklund G., Al-Orf N., Bhat R.S., Moubayed N., Abed K. Probiotic treatment reduces the autistic-like excitation/inhibition imbalance in juvenile hamsters induced by orally administered propionic acid and clindamycin. Metab. Brain Dis. 2018;33:1155–1164. doi: 10.1007/s11011-018-0212-8.
    1. Parracho H.M.R.T., Gibson G.R., Knott F., Bosscher D., Kleerebezem M., McCartney A.L. A double blind, placebo-controlled, crossover-designed probiotic feeding study in children diagnosed with autistic spectrum disorders. Int. J. Probiotics Prebiotics. 2010;5:69–74.
    1. Kaluzna-Czaplinska J., Blaszczyk S. The level of arabinitol in autistic children after probiotic therapy. Nutrition. 2012;28:124–126. doi: 10.1016/j.nut.2011.08.002.
    1. Pärtty A., Kalliomäki M., Wacklin P., Salminen S., Isolauri E. A possible link between early probiotic intervention and the risk of neuropsychiatric disorders later in childhood: A randomized trial. Pediatr. Res. 2015;77:823–828. doi: 10.1038/pr.2015.51.
    1. Blades M. Autism an interesting dietary case history. Nutr. Food Sci. 2000;30:137–139. doi: 10.1108/00346650010319741.
    1. Grossi E., Melli S., Dunca D., Terruzzi V. Unexpected improvement in core autism spectrum disorder symptoms after long-term treatment with probiotics. SAGE Open Med. Case Rep. 2016;4:2050313X16666231. doi: 10.1177/2050313X16666231.
    1. West R., Roberts E., Sichel L.S., Sichel J. Improvements in gastrointestinal symptoms among children with autism spectrum disorder receiving the DelproR probiotic and immunomodulatory formulation. J. Probiotics Health. 2013;1:2.
    1. Shaaban S.Y., El Gendy Y.G., Mehanna N.S., El-Senousy W.M., El-Feki H.S.A., Saad K., El-Asheer O.M. The role of probiotics in children with autism spectrum disorder: A prospective, open-label study. Nutr. Neurosci. 2017;21:676–681. doi: 10.1080/1028415X.2017.1347746.
    1. Belizário J.E., Napolitano M. Human microbiomes and their roles in dysbiosis, common diseases, and novel therapeutic approaches. Front. Microbiol. 2015;6:050. doi: 10.3389/fmicb.2015.01050.
    1. Liu F., Li J., Wu F., Zheng H., Peng Q., Zhou H. Altered composition and function of intestinal microbiota in autism spectrum disorders: A systematic review. Transl. Psychiatry. 2019;9:43. doi: 10.1038/s41398-019-0389-6.
    1. Fetissov S.O., Averina O.V., Danilenko V.N. Neuropeptides in the microbiota-brain axis and feeding behavior in autism spectrum disorder. Nutrition. 2018;61:43–48. doi: 10.1016/j.nut.2018.10.030.
    1. Obrenovich M.E., Donskey C.J., Schiefer I.T., Bongiovanni R., Li L., Jaskiw G.E. Quantification of phenolic acid metabolites in humans by LC-MS: A structural and targeted metabolomics approach. Bioanalysis. 2018;10:1591–1608. doi: 10.4155/bio-2018-0140.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa